Navigation Links
EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011
Date:6/24/2011

LONDON, June 24, 2011 /PRNewswire/ --


 

EP Vantage, part of EvaluatePharma, was presented with the coveted Commentator of the Year Award at the European Mediscience Awards, sponsored by Matrix, on June 22, 2011.

The award, which honours clear and concise commentary in the pharma and biotech sector, can be given to analysts, journalists, columnists, research houses or specialist websites dedicated to providing sharp, perceptive and penetrating commentary.

The EP Vantage team - Lisa Urquhart, Amy Brown, Christian Glennie and Jonathan Gardner - beat a strong field that included analysts and fellow journalists to claim the prize.

Speaking about the achievement Jonathan de Pass, chief executive of EvaluatePharma, said: "I'm thrilled that the EP Vantage team have won the European Mediscience 2011 Commentator of the Year award.

The life-science industry is well served for commentary by several long-established publications and by many securities analysts so this is all the more an incredible achievement given that EP Vantage has been going for less than four years. After twice being runners-up for this award, this is well-deserved recognition for the team."

Notes for Editors:

About EP Vantage

Launched in 2007 by EvaluatePharma, EP Vantage is a daily online comment and analysis service providing insightful, forward-looking financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A in the biotech and pharma industry.

Written by an experienced team of journalists, EP Vantage prides itself on covering market catalysts weeks and even months ahead of other industry sources.

EP Vantage's analysis is powered by EvaluatePharma, the leaders in consensus forecasts in the pharmaceutical industry for over 12 years.

EP Vantage editorial team

Lisa Urquhart, Editor

<
'/>"/>
SOURCE EvaluatePharma Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
6. St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors
7. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
8. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
9. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
10. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
11. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... , Sept. 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has granted orphan drug ... hypertension. "The FDA Office of Orphan ... from sponsors to identify and designate drug candidates that ... evaluation and development of such products," said Craig ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... SUNNYVALE, Calif., July 7, 2011 Cepheid (Nasdaq: ... for its 2011 second quarter ended June 30, 2011, on ... The company will host a management presentation at ... discuss the results.  To access the live webcast, please visit ...
... just three weeks after hearing oral argument, the First District ... judgment against Johnson & Johnson (NYSE: JNJ ) ... death case involving their Duragesic® fentanyl pain patch. ... in DiCosolo v. ALZA Corp, et al ., obtained ...
Cached Medicine Technology:Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 3
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
(Date:9/2/2014)... By Steven Reinberg ... (HealthDay News) -- Stimulant medications -- such as Adderall, ... (ADHD) in children, won,t stunt their growth, a new ... final height as adults," said study researcher Dr. Slavica ... Clinic in Rochester, Minn. Katusic noted that results ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 ... loss by blocking a certain nerve linked to appetite and ... patients. Using electric impulses to block the vagus nerve, ... suppress feelings of hunger. And, they did, just not to ... the nerve that connects the brain to the gut can ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Drinking and marijuana may ... a new study suggests. Researchers analyzed 2007 to ... school seniors who said they had used alcohol or ... drinking alcohol was associated with more unsafe driving, damage ... about actions while under the influence of alcohol, especially ...
Breaking Medicine News(10 mins):Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2
... be making us hungrier, so we eat more, which in ... Yang and his colleagues at the Lawson Health Research Institute ... tissue can reproduce a hormone that stimulates fat cell production. ... way we think about and treat abdominal obesity. , Yang ...
... 16 Skanska USA Building Inc.,announced today that ... service the,growing Indiana construction markets. The announcement was ... Midwest operations., "Indiana is a strong construction ... "Skanska is an industry leader and after,working in ...
... Facing the ... Healthcare Industry, ... with U.S. News & World Report,hosted an exclusive panel discussion ... National Press Club in Washington, D.C.,The event, attended by Congressional ...
... with a faulty breast cancer gene could be at ... genes, according to research published this month in the ... University of Pennsylvania School of Medicine join an international ... 10,000 women carrying a BRCA1 or BRCA2 mutation for ...
... the source should lead to more effective vaccines, researchers say ... strains of virus that produce seasonal flu epidemics start in ... of the world, researchers report. , And by focusing on ... to improve their forecast of seasonal flu strains and develop ...
... Ala. - New clinical data showed some cancer patients ... AME-133v, said a researcher at the University of Alabama ... 15th during the 2008 annual meeting of the American ... 1 clinical trial data showed AME-133v had a potent ...
Cached Medicine News:Health News:Your belly fat could be making you hungrier 2Health News:Skanska Opens Indianapolis Office 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3Health News:Breast cancer risk amplified by additional genes in combo with BRCA mutation 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: